The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The human NRXN2 gene (UniProt: Q9P2S2) encodes neurexin-2, a member of the neurexin family of presynaptic cell adhesion molecules (cuttler2021emergingevidenceimplicating pages 2-3, khoja2023advancesinneurexin pages 3-4). The gene is also known by the synonym KIAA0921 (chofflet2025alphaneurexinsinhealth pages 2-3). All retrieved scientific literature confirms that NRXN2 refers specifically to human neurexin-2, with consistent descriptions matching the UniProt annotation: a protein belonging to the neurexin family, containing laminin-G (LNS) and EGF-like domains, and functioning in synaptic organization (gomez2021neurexinsmolecularcodes pages 4-6, cuttler2021emergingevidenceimplicating pages 2-3). There is no ambiguity with other genes sharing this symbol.
NRXN2 encodes a presynaptic transmembrane cell-adhesion molecule that functions fundamentally differently from its paralogues NRXN1 and NRXN3 (lin2023neurexin2aninhibitory pages 1-2). Rather than being a substrate-specific enzyme or transporter, NRXN2 acts as a nonenzymatic molecular scaffold and synaptic organizer whose primary function is to restrict and regulate synapse formation (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4).
A landmark 2023 study published in Science Advances by Lin et al. established that NRXN2 functions as an "inhibitory neurexin" that actively restricts excitatory synapse formation in the hippocampus (lin2023neurexin2aninhibitory pages 1-2). This represents a unique and opposing functional role compared to NRXN1 and NRXN3, which generally promote synapse assembly (chofflet2024structuralandfunctional pages 16-17). Specifically, constitutive or neuron-specific deletion of Nrxn2 in mice nearly doubled the strength of excitatory CA3→CA1 synaptic connections, markedly increased presynaptic release probability, and approximately doubled the density of excitatory synapses in the hippocampal CA1 region (lin2023neurexin2aninhibitory pages 1-2). Critically, these effects were selective for excitatory synapses, with no detectable changes in inhibitory synapses (lin2023neurexin2aninhibitory pages 1-2).
This restrictive function persists throughout life: hippocampal NRXN2 deletion in mature adult mice also increased synaptic connectivity, demonstrating that NRXN2 continuously controls synaptic circuit dynamics rather than functioning only during development (lin2023neurexin2aninhibitory pages 1-2). The behavioral consequence of this dysregulation includes impaired cognitive flexibility in spatial memory tasks (lin2023neurexin2aninhibitory pages 1-2, khoja2024conditionaldeletionof pages 11-12).
NRXN2's molecular function is mediated through trans-synaptic adhesion complexes. Its extracellular domain recognizes and binds specific postsynaptic ligands across the synaptic cleft, while its short cytoplasmic tail couples these extracellular interactions to presynaptic structural and signaling machinery (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4, cuttler2021emergingevidenceimplicating pages 2-3). Through these bidirectional connections, NRXN2 specifies synapse number, identity, release properties, and overall circuit connectivity (gomez2021neurexinsmolecularcodes pages 4-6, chofflet2024structuralandfunctional pages 1-2).
Unlike enzymes with defined substrates, NRXN2's "substrate specificity" is determined by its binding partner repertoire, which is extensively regulated by alternative splicing (gomez2021neurexinsmolecularcodes pages 4-6). The molecular basis for NRXN2's unique anti-synaptogenic activity likely relates to its substantial sequence divergence from NRXN1 and NRXN3, particularly in the LNS1 domain, combined with its smaller gene size and distinct splice architecture (chofflet2024structuralandfunctional pages 16-17, khoja2023advancesinneurexin pages 3-4).
The human NRXN2 gene spans approximately 106.4 kilobases and contains 23 exons (chofflet2025alphaneurexinsinhealth pages 2-3). Like other neurexin genes, NRXN2 employs two independent promoters to generate structurally distinct protein isoforms (chofflet2025alphaneurexinsinhealth pages 2-3, cuttler2021emergingevidenceimplicating pages 2-3):
Both isoforms are type I single-pass transmembrane proteins but differ dramatically in their extracellular architecture (chofflet2025alphaneurexinsinhealth pages 2-3, chofflet2025alphaneurexinsinhealth pages 1-2).
NRXN2α Structure:
The alpha isoform contains an elaborate extracellular region comprising six laminin-neurexin-sex hormone-binding globulin (LNS) domains (LNS1–LNS6) interspersed with three epidermal growth factor-like (EGF) domains (EGF1–EGF3) (chofflet2025alphaneurexinsinhealth pages 2-3, gomez2021neurexinsmolecularcodes pages 4-6, chofflet2025alphaneurexinsinhealth pages 6-7). The LNS domains form β-sandwich structures containing calcium- and ligand-binding sites (gomez2021neurexinsmolecularcodes pages 4-6). The EGF-like domains provide flexible hinges between LNS modules, creating a structurally adaptable extracellular scaffold capable of engaging multiple synaptic partners (chofflet2025alphaneurexinsinhealth pages 2-3, chofflet2025alphaneurexinsinhealth pages 1-2).
NRXN2β Structure:
The beta isoform has a short, unique N-terminal histidine-rich domain followed by only the LNS6 module (corresponding to the sixth LNS domain of α-neurexin), thus lacking the upstream LNS1–5 and EGF domains (chofflet2025alphaneurexinsinhealth pages 2-3, cuttler2021emergingevidenceimplicating pages 3-3).
Conserved Regions:
Both isoforms share:
- An extensively O-glycosylated juxtamembrane stalk region (gomez2021neurexinsmolecularcodes pages 4-6)
- A single transmembrane helix (chofflet2025alphaneurexinsinhealth pages 2-3)
- A short cytoplasmic tail containing protein 4.1 interaction sites and a C-terminal PDZ-binding motif (chofflet2025alphaneurexinsinhealth pages 2-3, gomez2021neurexinsmolecularcodes pages 4-6, chofflet2025alphaneurexinsinhealth pages 6-7)
NRXN2 undergoes extensive alternative splicing at five principal splice sites (SS1–SS5) in the alpha isoform (chofflet2025alphaneurexinsinhealth pages 2-3, gomez2021neurexinsmolecularcodes pages 4-6). Notably, NRXN2 lacks the SS6 splice element found in NRXN1 and NRXN3, representing a key structural distinction (khoja2023advancesinneurexin pages 3-4, chofflet2025alphaneurexinsinhealth pages 6-7). Alternative splicing at SS4 (also termed AS4) is particularly important for modulating ligand-binding preferences: inclusion of the SS4 insert diminishes β-NRXN2's affinity for neuroligins while enabling binding to cerebellins (gomez2021neurexinsmolecularcodes pages 4-6).
Importantly, the functional consequences of splicing are not identical across neurexin family members. Unlike NRXN1 and NRXN3, where SS4 inclusion/exclusion affects AMPA and NMDA receptor regulation, the same splice variation in NRXN2 does not alter AMPAR or NMDAR function in the same way (khoja2023advancesinneurexin pages 3-4, khoja2023advancesinneurexin pages 4-5). This splice-isoform specificity is also activity-dependent: neuronal activation and calcium signaling promote exclusion of the Nrxn2 SS3 insert (liu2026rolesofnrxn1 pages 3-4).
NRXN2 is predominantly localized to the presynaptic plasma membrane at neuronal terminals (cuttler2021emergingevidenceimplicating pages 3-3, cuttler2021emergingevidenceimplicating pages 2-3). As a type I transmembrane protein, NRXN2 spans the neuronal membrane with its large extracellular domain projecting into the synaptic cleft to mediate trans-synaptic interactions, while its cytoplasmic tail remains intracellular and associates with presynaptic scaffolding proteins (cuttler2021emergingevidenceimplicating pages 2-3, chofflet2025alphaneurexinsinhealth pages 2-3).
NRXN2 carries out its function at both excitatory and inhibitory synapses, though with distinct roles at each (cuttler2021emergingevidenceimplicating pages 3-3, chofflet2024structuralandfunctional pages 1-2). During early human cortical development, NRXN2 is associated with axon-growth markers and presynaptic-terminal markers in proliferative cortical layers, suggesting a particularly important developmental role in early cortical synaptogenesis (khoja2023advancesinneurexin pages 3-4).
A minor postsynaptic pool of α-neurexins has been detected at the neurexin family level, particularly for regulating postsynaptic NMDA receptor function (chofflet2025alphaneurexinsinhealth pages 3-4), though this has not been definitively established for human NRXN2 specifically.
NRXN2 functions through selective interactions with postsynaptic ligands and intracellular scaffolding proteins. The following table summarizes the major binding partners:
| Binding partner / ligand | NRXN2 isoform and evidence specificity | Interaction domains / determinants | Binding affinity | Functional consequence | Location / synapse type |
|---|---|---|---|---|---|
| IgSF21 | NRXN2α-specific; no detectable binding to NRXN1α, NRXN3α, or tested β-neurexins | IgSF21 Ig1 domain binds NRXN2α LNS1; predicted interface joins IgSF21 residues around R53–D76 to the NRXN2α LNS1 β11–β12 loop around L161–Y171. The interaction is calcium-independent; IgSF21 Ig3 may contribute secondarily. | KD ≈ 5.7 nM, 1:1 interaction | Required for IgSF21-induced GABAergic presynaptic differentiation; preferentially organizes dendritic inhibitory contacts and engages JNK-dependent signaling during formation of new presynaptic specializations | Presynaptic NRXN2α–postsynaptic IgSF21 bridge at dendritic GABAergic synapses (chofflet2024structuralandfunctional pages 1-2, chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 9-10, chofflet2024structuralandfunctional pages 7-9, chofflet2024structuralandfunctional pages 6-7) |
| Neuroligins, including NLGN1 and NLGN2 | β-NRXN2 binds all neuroligins; α-neurexin binding depends on ligand and splice context. NLGN2–NRXN interactions are established, but many data are neurexin-family rather than uniquely NRXN2-specific. | Neuroligin extracellular acetylcholinesterase-like domain contacts NRXN2 LNS6; binding involves a calcium-coordinating neurexin surface and is modulated by NRXN2 AS4/SS4 and neuroligin splice inserts. Neurexin heparan sulfate can provide an additional cooperative contact. | β-NRXN2–neuroligin binding is reported in the nanomolar range; exact isoform-specific values were not provided | Forms trans-synaptic adhesion complexes that organize synaptic machinery. NLGN1 is associated mainly with excitatory organization; NLGN2 organizes inhibitory postsynaptic scaffolds and principally perisomatic inhibitory differentiation. NLGN2-linked synaptogenesis requires JNK and additionally CaMKII/Src signaling. | Excitatory and inhibitory synapses; NLGN2 is enriched at GABAergic/perisomatic inhibitory synapses (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4, chofflet2024structuralandfunctional pages 1-2, boxer2022neurexinsandtheir pages 9-10) |
| LRRTM1 / LRRTM2 | Demonstrated for neurexins including β-NRXN2; interaction is splice-state dependent. A pathogenic NRXN2 truncation preventing membrane anchoring also abolished LRRTM2 binding. | LRRTM extracellular LRR region engages NRXN2 LNS6 and cooperatively contacts neurexin-associated heparan sulfate; binding is favored by AS4/SS4-negative neurexin forms. | Not specified | Promotes trans-synaptic macromolecular assembly and excitatory synapse organization; loss of membrane anchoring or ligand binding is expected to impair synaptic adhesion and signaling | Predominantly excitatory/glutamatergic synapses (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4, khoja2023advancesinneurexin pages 3-4) |
| Cerebellins (CBLNs) | Applicable to NRXN2 splice isoforms carrying the appropriate AS4/SS4 insertion; much functional evidence is neurexin-family level | Cerebellins bind the terminal LNS6/β-LNS region; ligand selection is switched by AS4/SS4 inclusion | Not specified | Creates tripartite trans-synaptic organizing complexes and specifies synapse properties; illustrates how NRXN2 alternative splicing redirects ligand preference away from LRRTMs toward cerebellins | Circuit-dependent synapses, especially cerebellin-expressing neuronal pathways (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4) |
| Neurexophilins (NXPH1–4) | α-neurexin ligands; direct NRXN2α binding is plausible from family evidence, but the cited structural details derive mainly from NRXN1α | Primarily α-neurexin LNS2; SS2 insertion can enhance neurexophilin binding | Not specified | Contributes to α-neurexin-dependent synaptic specification and inhibitory-circuit organization; an NRXN2-specific physiological effect remains incompletely resolved | Extracellular/synaptic-cleft complexes, particularly in selected inhibitory circuits (chofflet2025alphaneurexinsinhealth pages 6-7, boxer2022neurexinsandtheir pages 8-9, chofflet2025alphaneurexinsinhealth pages 2-3) |
| α-Dystroglycan | Ligand of α- and β-neurexins; direct NRXN2-specific evidence in the cited material is limited | Can engage α-neurexin LNS2 and LNS6; interaction depends on neurexin splice state and dystroglycan O-glycosylation | Not specified | Supports trans-synaptic adhesion and context-dependent organization of inhibitory synapses | Synaptic cleft, with reported importance at selected inhibitory synapses (li2022modulationoftranssynaptic pages 2-4, chofflet2025alphaneurexinsinhealth pages 6-7, boxer2022neurexinsandtheir pages 8-9) |
| CASK, Mint proteins, Protein 4.1, syntenin | Conserved intracellular partners expected for both NRXN2α and NRXN2β; evidence is largely neurexin-family level | Short cytoplasmic tail: C-terminal PDZ-binding motif recruits PDZ-domain scaffolds; a separate site binds Protein 4.1 | Not specified | Couples extracellular adhesion to presynaptic scaffolding, cytoskeletal organization, synaptic vesicles, and release machinery | Cytoplasmic face of the presynaptic plasma membrane/active zone (li2022modulationoftranssynaptic pages 2-4, boxer2022neurexinsandtheir pages 8-9, cuttler2021emergingevidenceimplicating pages 2-3) |
Table: Major extracellular ligands and intracellular partners of NRXN2, with isoform, structural, affinity, and synaptic-context information. The table distinguishes NRXN2-specific evidence—strongest for IgSF21—from interactions supported mainly at the broader neurexin-family level.
The most clearly established NRXN2-specific interaction is with IgSF21 (Immunoglobulin Superfamily Member 21), a postsynaptic adhesion molecule (chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 7-9). This interaction is highly selective: IgSF21 binds NRXN2α but not NRXN1α, NRXN3α, or tested β-neurexin isoforms (chofflet2024structuralandfunctional pages 7-9, chofflet2024structuralandfunctional pages 6-7).
Structural Basis:
Recent structural modeling (2024) using AlphaFold2 combined with extensive mutagenesis revealed that the IgSF21 Ig1 immunoglobulin domain binds to the NRXN2α LNS1 domain (chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 9-10). The predicted interface involves the IgSF21 Ig1 β-sheet region (residues R53–D76) contacting the NRXN2α LNS1 β11–β12 loop (residues L161–Y171) through an extensive hydrogen-bonding network and hydrophobic contacts (chofflet2024structuralandfunctional pages 9-10). The interaction is calcium-independent and occurs with high affinity (KD ≈ 5.7 nM) in a 1:1 stoichiometry (chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 6-7).
Functional Consequence:
The IgSF21–NRXN2α complex is required for IgSF21-induced GABAergic presynaptic differentiation, specifically at dendritic (rather than perisomatic) inhibitory synapses (chofflet2024structuralandfunctional pages 1-2, chofflet2024structuralandfunctional pages 7-9). When IgSF21 is presented on contacting cells, it induces accumulation of the inhibitory vesicle marker VGAT on wild-type axons but not on Nrxn2α-knockout axons, demonstrating that NRXN2α is absolutely required for this synaptogenic activity (chofflet2024structuralandfunctional pages 7-9).
β-NRXN2 binds all neuroligins with nanomolar affinity through its LNS6 domain (gomez2021neurexinsmolecularcodes pages 4-6). This binding is modulated by alternative splicing at SS4 and involves calcium-dependent surfaces on the neurexin hypervariable region (gomez2021neurexinsmolecularcodes pages 4-6). Neuroligin-2 (NLGN2) is particularly important for organizing inhibitory postsynaptic scaffolds, primarily at perisomatic inhibitory synapses (chofflet2024structuralandfunctional pages 1-2, boxer2022neurexinsandtheir pages 9-10). A pathogenic NRXN2 truncation that prevented membrane anchoring also abolished binding to both NLGN2 and LRRTM2, demonstrating the functional importance of these interactions (khoja2023advancesinneurexin pages 3-4).
Additional binding partners include LRRTM1/2 (leucine-rich repeat transmembrane proteins), which bind the LNS6 region in a splice-dependent manner favoring SS4-negative forms (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4); cerebellins, which bind SS4-positive neurexin states (gomez2021neurexinsmolecularcodes pages 4-6); and family-level ligands including neurexophilins, dystroglycan, calsyntenin-3, and latrophilins (li2022modulationoftranssynaptic pages 2-4, chofflet2025alphaneurexinsinhealth pages 6-7, boxer2022neurexinsandtheir pages 8-9), though NRXN2-specific evidence for these remains limited.
A critical recent discovery (2024) identified the c-Jun N-terminal kinase (JNK) pathway as essential for NRXN2α-mediated inhibitory synapse organization (chofflet2024structuralandfunctional pages 1-2). Both the IgSF21–NRXN2α complex and the neuroligin-2–neurexin complex require JNK activity for their synaptogenic effects (chofflet2024structuralandfunctional pages 1-2). Pharmacological JNK inhibition reduces formation of new presynaptic specializations without disrupting already-established synapses, indicating that JNK functions specifically in synapse development rather than maintenance (chofflet2024structuralandfunctional pages 1-2).
Importantly, loss of NRXN2α alters synaptic JNK activity in a sex-specific manner, supporting functional linkage between neurexin signaling and JNK pathways (chofflet2024structuralandfunctional pages 1-2). However, different neurexin ligands engage distinct downstream requirements: while both IgSF21–NRXN2α and neuroligin-2–neurexin signaling require JNK, neuroligin-2 additionally depends on CaMKII and Src kinase activity, whereas IgSF21 does not (chofflet2024structuralandfunctional pages 1-2). These differential requirements may contribute to the distinct synaptic compartment specificities of these complexes.
At the presynaptic level, NRXN2 regulates calcium-dependent neurotransmitter release mechanisms (khoja2023advancesinneurexin pages 5-6, juanes2026neurexin3βis pages 18-21, tromp2021neurexinsinautism pages 5-6). The neurexin family, including NRXN2, helps organize voltage-gated calcium channels at the presynaptic active zone, coupling calcium entry to synaptic vesicle exocytosis (juanes2026neurexin3βis pages 18-21, li2022modulationoftranssynaptic pages 2-4). NRXN2 deletion leads to altered release probability at hippocampal excitatory synapses, with neuron-specific deletion producing increased release probability in CA1 (khoja2023advancesinneurexin pages 5-6, lin2023neurexin2aninhibitory pages 1-2).
NRXN2α plays a particularly important role in regulating NMDA receptor (NMDAR) function at excitatory synapses (chofflet2025alphaneurexinsinhealth pages 5-6). Deletion of NRXN2α selectively reduces NMDAR-mediated transmission, shortens NMDAR-EPSC decay, and alters paired-pulse facilitation (khoja2023advancesinneurexin pages 4-5, chofflet2025alphaneurexinsinhealth pages 5-6). Importantly, additional deletion of NRXN2β does not substantially worsen these phenotypes, identifying NRXN2α as the principal isoform for NMDAR regulation (chofflet2025alphaneurexinsinhealth pages 5-6).
The NRXN2 cytoplasmic tail couples extracellular adhesion to intracellular machinery through interactions with CASK, Mint proteins, protein 4.1, and syntenin (li2022modulationoftranssynaptic pages 2-4, boxer2022neurexinsandtheir pages 8-9). These interactions link NRXN2 to cytoskeletal elements, presynaptic scaffolds, synaptic vesicles, and the neurotransmitter release machinery (li2022modulationoftranssynaptic pages 2-4, cuttler2021emergingevidenceimplicating pages 2-3).
NRXN2 plays a critical role in maintaining appropriate hippocampal circuit connectivity and excitation/inhibition balance. Conditional deletion in the hippocampus and cortex (Emx1-Nrxn2 cKO) increased hippocampal network activity, measured by higher frequencies of spontaneous excitatory and inhibitory postsynaptic currents (khoja2023advancesinneurexin pages 5-6). This network hyperexcitability occurred without detectable changes in neurotransmitter release probability or the relative contributions of AMPA and NMDA receptors, suggesting circuit-level reorganization (khoja2023advancesinneurexin pages 5-6).
Most strikingly, these circuit alterations manifested as spontaneous recurrent seizures in Nrxn2 conditional knockout mice, representing the first direct evidence that NRXN2 loss can produce epileptiform activity (lin2023neurexin2aninhibitory pages 1-2, khoja2023advancesinneurexin pages 5-6).
Recent studies (2023-2024) have established that NRXN2 is essential for behavioral flexibility and adaptive updating of action–outcome contingencies (khoja2024conditionaldeletionof pages 11-12). Conditional deletion of Nrxn2 impaired reversal learning and the ability to disengage from previously established behavioral patterns (khoja2024conditionaldeletionof pages 11-12). These mice showed difficulty updating their behavior when action–outcome relationships changed, manifesting as:
The neural basis appears to involve altered cortical-striatal circuits, particularly the cingulate cortex (Cg1/M2) projections to dorsomedial striatum, which shift behavior toward habitual systems (khoja2024conditionaldeletionof pages 11-12).
Both homozygous and heterozygous Nrxn2α knockout mice show diminished social approach, reduced responses to social novelty, and impaired recognition of novel objects (gomez2021neurexinsmolecularcodes pages 10-12). These behavioral phenotypes align with the gene's association with autism spectrum disorder.
NRXN2 mutations and variants have been identified in multiple neurodevelopmental and neuropsychiatric disorders, though the clinical evidence base remains more limited than for NRXN1 (chofflet2025alphaneurexinsinhealth pages 11-12, tromp2021neurexinsinautism pages 11-11):
Autism Spectrum Disorder (ASD): Truncating variants in NRXN2 have been reported in ASD patients (tromp2021neurexinsinautism pages 11-11). A functionally characterized truncating mutation prevented NRXN2 from anchoring in the plasma membrane and abolished its binding to the postsynaptic partners LRRTM2 and NLGN2 (khoja2023advancesinneurexin pages 3-4). This demonstrates how loss-of-function mutations disrupt NRXN2's critical trans-synaptic adhesion role.
Epilepsy: A severe case of early-onset epileptic encephalopathy with fatal respiratory failure involved heterozygous missense variants in both NRXN1α and NRXN2α (digenic inheritance) (chofflet2025alphaneurexinsinhealth pages 11-12, tromp2021neurexinsinautism pages 11-11, khoja2023advancesinneurexin pages 10-10). The NRXN2α variant was inherited from a father with febrile seizures, suggesting potential pathogenicity, though the digenic nature prevents clear attribution to NRXN2 alone.
Intellectual Disability and Developmental Delay: NRXN2 deletions and mutations are associated with intellectual disability and neurodevelopmental delay (khoja2023advancesinneurexin pages 3-4, tromp2021neurexinsinautism pages 11-11).
Schizophrenia: While NRXN1 has strong schizophrenia associations, current evidence does not firmly establish NRXN2 as an independent schizophrenia risk gene, though some studies have reported associations (chofflet2025alphaneurexinsinhealth pages 11-12, tromp2021neurexinsinautism pages 11-11).
The mechanistic consequences of NRXN2 disruption include:
- Loss of membrane localization (khoja2023advancesinneurexin pages 3-4)
- Abolished trans-synaptic ligand binding (khoja2023advancesinneurexin pages 3-4)
- Disrupted excitation/inhibition balance (lin2023neurexin2aninhibitory pages 1-2, khoja2023advancesinneurexin pages 5-6)
- Altered synaptic connectivity and density (lin2023neurexin2aninhibitory pages 1-2, khoja2023advancesinneurexin pages 5-6)
- Network hyperexcitability and seizure susceptibility (khoja2023advancesinneurexin pages 5-6)
Anti-Synaptogenic Function (Lin et al., Science Advances, 2023): Established NRXN2 as uniquely restrictive for excitatory synapse formation, with nearly 2-fold increases in hippocampal synapse density and strength upon deletion (lin2023neurexin2aninhibitory pages 1-2).
IgSF21–NRXN2α Structural Complex (Chofflet et al., Frontiers in Molecular Neuroscience, 2024): First detailed structural characterization of the NRXN2α–IgSF21 binding interface using AlphaFold2 modeling and extensive mutagenesis (chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 9-10). Identified the LNS1–Ig1 domain interaction as the structural basis for selective GABAergic synapse organization.
JNK Signaling Pathway (Chofflet et al., 2024): Discovery that IgSF21–NRXN2α synaptogenesis requires JNK-mediated signaling, with sex-specific alterations in synaptic JNK activity following NRXN2 loss (chofflet2024structuralandfunctional pages 1-2).
Behavioral Flexibility Deficits (Khoja & Chen, Scientific Reports, 2024): Demonstrated that NRXN2 deletion impairs behavioral flexibility and action–outcome updating, linking molecular mechanisms to complex cognitive functions (khoja2024conditionaldeletionof pages 11-12).
Seizure Susceptibility (Haile et al., 2023): First direct evidence that conditional NRXN2 deletion produces spontaneous recurrent seizures, establishing a causal link to epilepsy (khoja2023advancesinneurexin pages 5-6).
Recent reviews emphasize several critical gaps and opportunities (chofflet2025alphaneurexinsinhealth pages 11-12, khoja2024conditionaldeletionof pages 11-12):
- Need for standardized animal and human iPSC models
- Expansion of research beyond NRXN1 to better characterize NRXN2 and NRXN3
- Investigation of sex-specific effects and mechanisms
- Development of splice-isoform-specific therapeutic strategies
- Understanding cell-type-specific NRXN2 functions across brain regions
NRXN2 is currently employed as:
1. Disease Model Systems: Conditional knockout mice map circuit-specific functions and model neurodevelopmental disorders (khoja2024conditionaldeletionof pages 11-12)
2. Molecular Probes: Ligand-binding assays and mutagenesis experiments elucidate trans-synaptic organizing mechanisms (chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 7-9)
3. Genomic Interpretation: Patient sequencing identifies candidate pathogenic variants for diagnostic purposes (khoja2023advancesinneurexin pages 3-4)
While no validated NRXN2-directed therapies currently exist, potential future applications include:
- Splice-modulating therapeutics: Targeting specific NRXN2 splice isoforms to restore balanced synaptic function
- Synapse-stabilizing agents: Modulating NRXN2–ligand interactions to correct circuit hyperexcitability
- Precision medicine: Genotype-guided interventions for NRXN2 mutation carriers
- Biomarker development: NRXN2 splice variants or IgSF21 complex levels as potential disease biomarkers
The following comprehensive tables summarize the key structural, functional, and mechanistic properties of NRXN2:
| Category | NRXN2 annotation | Evidence and qualification |
|---|---|---|
| Gene and protein identity | Gene: NRXN2 (synonym KIAA0921); protein: neurexin-2/neurexin-2α; UniProt: Q9P2S2; organism: Homo sapiens. | The identity is concordant with literature describing human NRXN2 as one of the three mammalian neurexin genes; no symbol ambiguity was detected. (cuttler2021emergingevidenceimplicating pages 2-3, chofflet2025alphaneurexinsinhealth pages 2-3) |
| Protein family | Neurexin-family neuronal cell-adhesion and synapse-organizing protein; a type-I, single-pass transmembrane glycoprotein. | Neurexins connect extracellular synaptic-recognition complexes to intracellular presynaptic scaffolds. (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4) |
| Primary molecular function | A predominantly presynaptic, nonenzymatic adhesion receptor and molecular scaffold. Its extracellular region recognizes ligands across the synaptic cleft, while its cytoplasmic tail couples those interactions to presynaptic structural and signaling machinery. It therefore specifies and regulates synapse number, identity, release properties, and connectivity rather than catalyzing a reaction or transporting a substrate. (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4, cuttler2021emergingevidenceimplicating pages 2-3) | The strongest NRXN2-specific physiological evidence indicates that it continuously restrains excitatory hippocampal synapse assembly and presynaptic release probability. (lin2023neurexin2aninhibitory pages 1-2) |
| Isoforms and structural organization | Separate promoters generate long α and shorter β isoforms. NRXN2α has six extracellular laminin/neurexin/sex-hormone-binding-globulin (LNS/LG) domains and three interspersed EGF-like domains; NRXN2β has a short isoform-specific N terminus followed principally by the shared LNS6 module. Both contain a glycosylated juxtamembrane stalk, one transmembrane helix, and a short cytoplasmic tail with Protein 4.1 interaction sites and a C-terminal PDZ-binding motif. (chofflet2025alphaneurexinsinhealth pages 2-3, gomez2021neurexinsmolecularcodes pages 4-6) | This architecture agrees with the supplied InterPro annotations: ConA-like/Laminin-G, EGF, neurexin-like, and neurexin-related C-terminal regions. LNS domains provide calcium- and ligand-binding surfaces; the EGF modules contribute flexible hinges. (gomez2021neurexinsmolecularcodes pages 4-6, chofflet2025alphaneurexinsinhealth pages 1-2) |
| Molecular diversification | Alternative promoter use, alternative transcription, and extensive splicing create context-specific ligand-binding repertoires. NRXN2α is described as using five principal splice sites (SS1–SS5) and lacks the SS6 element found in NRXN1/3; splice variation at SS4 modifies ligand preferences, including β-NRXN2 affinity for neuroligins. (khoja2023advancesinneurexin pages 3-4, chofflet2025alphaneurexinsinhealth pages 2-3, gomez2021neurexinsmolecularcodes pages 4-6) | Splice-state effects should not automatically be extrapolated among paralogs: unlike NRXN1/3, experimentally forcing NRXN2 SS4 inclusion did not reproduce changes in AMPAR- or NMDAR-mediated currents. (khoja2023advancesinneurexin pages 3-4, khoja2023advancesinneurexin pages 4-5) |
| Subcellular localization and functional site | Predominantly localized to the presynaptic plasma membrane of neuronal terminals at excitatory and inhibitory synapses. Its ectodomain projects into the synaptic cleft to bind postsynaptic ligands; its short tail remains cytoplasmic and associates with presynaptic adaptors. A smaller postsynaptic α-neurexin pool is possible at the family level but is not firmly resolved for human NRXN2. (cuttler2021emergingevidenceimplicating pages 3-3, cuttler2021emergingevidenceimplicating pages 2-3, chofflet2025alphaneurexinsinhealth pages 3-4) | Developmental human-brain observations associate NRXN2 with axon-growth and presynaptic-terminal markers in early cortical layers, although much mechanistic localization evidence comes from rodent neurons. (khoja2023advancesinneurexin pages 3-4) |
| Key extracellular binding partners | IgSF21: highly selective for NRXN2α; postsynaptic IgSF21 Ig1 binds presynaptic NRXN2α LNS1 with approximately 5.7 nM affinity and 1:1 stoichiometry, promoting dendritic GABAergic presynaptic differentiation. Neuroligins: β-NRXN2 binds neuroligins with nanomolar affinity through LNS6, modulated by SS4 and calcium-dependent surfaces. LRRTM1/2: bind the LNS6/heparan-sulfate region in a splice-dependent manner. Cerebellins: favor SS4-positive neurexin states. Other family-level candidate ligands include neurexophilins, dystroglycan, calsyntenin-3, latrophilins, and GABA-receptor-related molecules, but these should not all be assumed to be NRXN2-specific. (gomez2021neurexinsmolecularcodes pages 4-6, li2022modulationoftranssynaptic pages 2-4, chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 7-9, chofflet2024structuralandfunctional pages 6-7) | The IgSF21 interaction is the most clearly established NRXN2α-selective ligand relationship: the modeled contact involves the IgSF21 Ig1 β-sheet and NRXN2α LNS1 β11–β12 loop, is calcium-independent, and is supported by interface mutagenesis. (chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 9-10) |
| Intracellular partners | The conserved neurexin tail can bind CASK, Mint proteins, syntenin, Protein 4.1, and reported synaptic-vesicle-associated proteins, linking trans-synaptic recognition to cytoskeletal organization and release machinery. (li2022modulationoftranssynaptic pages 2-4, boxer2022neurexinsandtheir pages 8-9) | These intracellular interactions are well established for the neurexin family, but the degree to which each is specifically required for human NRXN2 signaling remains incompletely resolved. |
| Unique role relative to NRXN1/NRXN3 | In mouse hippocampus, NRXN2 acts as an anti-synaptogenic or restrictive organizer, whereas NRXN1 and NRXN3 are more commonly synapse-supporting. Constitutive or neuron-selective Nrxn2 loss nearly doubled excitatory CA3→CA1 connection strength and excitatory CA1 synapse density and increased release probability, without a detected effect on inhibitory synapses. Adult deletion also increased connectivity, indicating an ongoing role beyond development. (chofflet2024structuralandfunctional pages 16-17, lin2023neurexin2aninhibitory pages 1-2) | The exact molecular mechanism producing this opposing output remains unresolved. Sequence divergence—especially in LNS1—and the smaller gene/splice architecture are plausible contributors, but are not yet a complete mechanistic explanation. (chofflet2024structuralandfunctional pages 16-17, khoja2023advancesinneurexin pages 3-4) |
| Excitatory-synapse function | Restricts hippocampal excitatory synapse number and strength, controls release probability, and contributes to glutamatergic receptor regulation. Earlier Nrxn2α models also reported altered NMDAR-mediated transmission and facilitation, demonstrating that phenotypes depend on isoform, region, developmental timing, and deletion strategy. (lin2023neurexin2aninhibitory pages 1-2, khoja2023advancesinneurexin pages 4-5, chofflet2025alphaneurexinsinhealth pages 5-6) | The most direct quantitative findings are an approximately twofold increase in CA1 excitatory synapse density and nearly doubled CA3→CA1 strength after deletion. (lin2023neurexin2aninhibitory pages 1-2) |
| Inhibitory-synapse function | NRXN2α serves as the presynaptic receptor for postsynaptic IgSF21 and is required for IgSF21-induced dendritic GABAergic presynaptic differentiation. This is compartment-specific: neuroligin-2–neurexin signaling acts more strongly at perisomatic inhibitory synapses. NRXN2 loss alone does not uniformly disrupt basal inhibitory transmission, so its GABAergic role is ligand-, compartment-, and circuit-dependent. (chofflet2024structuralandfunctional pages 1-2, chofflet2025alphaneurexinsinhealth pages 5-6, chofflet2024structuralandfunctional pages 7-9) | IgSF21 presented by contacting cells induced VGAT accumulation on wild-type but not Nrxn2α-null axons, providing direct functional evidence for this trans-synaptic pathway. (chofflet2024structuralandfunctional pages 7-9) |
| Major signaling pathways | IgSF21–NRXN2α–JNK axis: c-Jun N-terminal kinase activity is required for formation of new IgSF21-induced presynaptic specializations but not maintenance of established synapses; Nrxn2α loss alters synaptic JNK activity in a sex-dependent manner. Neuroligin-2–neurexin signaling: also requires JNK and, unlike IgSF21 signaling, additionally depends on CaMKII and Src. Presynaptic organization: family-level mechanisms connect neurexins to calcium-channel positioning, calcium-triggered vesicle release, cytoskeletal adaptors, and postsynaptic receptor/scaffold organization. (chofflet2024structuralandfunctional pages 1-2, li2022modulationoftranssynaptic pages 2-4) | JNK coupling is experimentally supported in cultured/rodent systems, but the direction and intervening molecular components between presynaptic NRXN2 and postsynaptic pathway activation are not completely defined. |
| Biological-process and circuit consequences | Maintains appropriate excitation/inhibition and synaptic connectivity; influences hippocampal circuit excitability, cognitive flexibility, social behavior, and action–outcome updating. Conditional cortical/hippocampal loss increased network activity and produced spontaneous recurrent seizures in mice; targeted deletion also impaired reversal learning and adaptation to changed action–outcome contingencies. (khoja2023advancesinneurexin pages 5-6, khoja2024conditionaldeletionof pages 11-12) | These are mechanistic animal-model outcomes rather than proof that identical behavioral effects follow every human NRXN2 variant. |
| Human clinical associations | Rare deletions, truncating variants, and other NRXN2 alterations have been reported in autism spectrum disorder, developmental delay/intellectual disability, epilepsy, and occasionally schizophrenia-related cohorts. A truncating variant impaired membrane anchoring and abolished LRRTM2/NLGN2 binding. A severe early epileptic-encephalopathy case carried variants in both NRXN1α and NRXN2α, preventing attribution to NRXN2 alone. (khoja2023advancesinneurexin pages 3-4, chofflet2025alphaneurexinsinhealth pages 11-12, tromp2021neurexinsinautism pages 11-11) | Clinical evidence remains sparse relative to NRXN1, with variable inheritance and limited penetrance data. Associations support NRXN2 as a candidate neurodevelopmental-risk gene, not a single-gene diagnostic explanation in most patients. (chofflet2025alphaneurexinsinhealth pages 11-12, khoja2023advancesinneurexin pages 10-10) |
| Current applications and translational status | Present applications are primarily research and genomic interpretation: conditional knockout animals map circuit-specific functions; ligand-binding and mutagenesis assays test molecular mechanisms; and patient sequencing identifies candidate variants. NRXN2/IgSF21 and splice-specific complexes may eventually provide therapeutic or biomarker hypotheses, but no validated NRXN2-directed drug, clinical biomarker, or approved therapy was identified in the reviewed evidence. (khoja2024conditionaldeletionof pages 11-12, chofflet2024structuralandfunctional pages 16-17, chofflet2024structuralandfunctional pages 7-9) | Expert reviews emphasize the need for standardized animal and human iPSC models and more direct study of NRXN2/NRXN3 because they remain substantially less characterized than NRXN1. |
Table: This table integrates verified identity, architecture, localization, ligand interactions, pathways, physiological evidence, and clinical relevance for human NRXN2/Q9P2S2. It distinguishes NRXN2-specific findings from broader neurexin-family inferences and highlights major uncertainties.
NRXN2 encodes a presynaptic cell-adhesion molecule with a unique anti-synaptogenic function that distinguishes it from other neurexin family members. As a molecular scaffold rather than an enzyme or transporter, NRXN2 continuously restricts excitatory synapse formation throughout life while organizing specific inhibitory synaptic contacts through selective ligand interactions. The protein's elaborate domain architecture—featuring six LNS domains and three EGF-like domains in the alpha isoform—enables diverse trans-synaptic interactions that are extensively regulated by alternative splicing and ligand availability.
Recent structural and functional studies (2023-2024) have revolutionized understanding of NRXN2, revealing its selective high-affinity interaction with IgSF21 through a precisely defined LNS1–Ig1 interface, its requirement for JNK-mediated signaling in inhibitory synapse organization, and its critical role in behavioral flexibility and seizure susceptibility. Human genetic studies implicate NRXN2 in autism, epilepsy, and intellectual disability, though the clinical evidence base remains more limited than for NRXN1.
The primary function of NRXN2 is to act as a context-dependent specifier of synaptic properties, maintaining appropriate circuit connectivity through trans-synaptic adhesion, intracellular scaffolding, and regulation of neurotransmitter release and receptor function. Its unique restrictive role at excitatory synapses—nearly doubling synapse density when deleted—positions NRXN2 as an essential brake on excitatory connectivity that prevents circuit hyperexcitability and enables adaptive behavioral flexibility.
References
(cuttler2021emergingevidenceimplicating pages 2-3): Katelyn Cuttler, Maryam Hassan, Jonathan Carr, Ruben Cloete, and Soraya Bardien. Emerging evidence implicating a role for neurexins in neurodegenerative and neuropsychiatric disorders. Open Biology, Oct 2021. URL: https://doi.org/10.1098/rsob.210091, doi:10.1098/rsob.210091. This article has 68 citations and is from a peer-reviewed journal.
(khoja2023advancesinneurexin pages 3-4): Sheraz Khoja, Mulatwa T. Haile, and Lulu Y. Chen. Advances in neurexin studies and the emerging role of neurexin-2 in autism spectrum disorder. Frontiers in Molecular Neuroscience, Feb 2023. URL: https://doi.org/10.3389/fnmol.2023.1125087, doi:10.3389/fnmol.2023.1125087. This article has 38 citations.
(chofflet2025alphaneurexinsinhealth pages 2-3): Nicolas Chofflet, Manni Wang, Mathilde Chofflet, and Hideto Takahashi. Alpha-neurexins in health and disease. Frontiers in Molecular Neuroscience, Nov 2025. URL: https://doi.org/10.3389/fnmol.2025.1716782, doi:10.3389/fnmol.2025.1716782. This article has 4 citations.
(gomez2021neurexinsmolecularcodes pages 4-6): Andrea M. Gomez, Lisa Traunmüller, and Peter Scheiffele. Neurexins: molecular codes for shaping neuronal synapses. Nature Reviews Neuroscience, 22:137-151, Jan 2021. URL: https://doi.org/10.1038/s41583-020-00415-7, doi:10.1038/s41583-020-00415-7. This article has 276 citations and is from a highest quality peer-reviewed journal.
(lin2023neurexin2aninhibitory pages 1-2): Pei-Yi Lin, Lulu Y. Chen, Man Jiang, Justin H. Trotter, Erica Seigneur, and Thomas C. Südhof. Neurexin-2: an inhibitory neurexin that restricts excitatory synapse formation in the hippocampus. Science Advances, Jan 2023. URL: https://doi.org/10.1126/sciadv.add8856, doi:10.1126/sciadv.add8856. This article has 52 citations and is from a highest quality peer-reviewed journal.
(li2022modulationoftranssynaptic pages 2-4): Huili Li, Ruijuan Guo, Yun Guan, Junfa Li, and Yun Wang. Modulation of trans-synaptic neurexin–neuroligin interaction in pathological pain. Cells, 11:1940, Jun 2022. URL: https://doi.org/10.3390/cells11121940, doi:10.3390/cells11121940. This article has 18 citations.
(chofflet2024structuralandfunctional pages 16-17): Nicolas Chofflet, Yusuke Naito, Anthony John Pastore, Nirmala Padmanabhan, Phuong Trang Nguyen, Christian Poitras, Benjamin Feller, Nayoung Yi, Jeremie Van Prooijen, Husam Khaled, Benoit Coulombe, Steven J. Clapcote, Steve Bourgault, Tabrez J. Siddiqui, Gabby Rudenko, and Hideto Takahashi. Structural and functional characterization of the igsf21-neurexin2α complex and its related signaling pathways in the regulation of inhibitory synapse organization. Frontiers in Molecular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fnmol.2024.1371145, doi:10.3389/fnmol.2024.1371145. This article has 9 citations.
(khoja2024conditionaldeletionof pages 11-12): Sheraz Khoja and Lulu Y. Chen. Conditional deletion of neurexin-2 impaired behavioral flexibility to alterations in action–outcome contingency. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60760-w, doi:10.1038/s41598-024-60760-w. This article has 3 citations and is from a peer-reviewed journal.
(chofflet2024structuralandfunctional pages 1-2): Nicolas Chofflet, Yusuke Naito, Anthony John Pastore, Nirmala Padmanabhan, Phuong Trang Nguyen, Christian Poitras, Benjamin Feller, Nayoung Yi, Jeremie Van Prooijen, Husam Khaled, Benoit Coulombe, Steven J. Clapcote, Steve Bourgault, Tabrez J. Siddiqui, Gabby Rudenko, and Hideto Takahashi. Structural and functional characterization of the igsf21-neurexin2α complex and its related signaling pathways in the regulation of inhibitory synapse organization. Frontiers in Molecular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fnmol.2024.1371145, doi:10.3389/fnmol.2024.1371145. This article has 9 citations.
(liu2026rolesofnrxn1 pages 1-2): Jia-Xiang Liu, Yanxuan Zhang, Ruijia Jin, Yuxin Zhu, and Jian-Ru Chen. Roles of nrxn1 in neuropsychiatric disorders: from genetic lesion to molecular mechanism. Frontiers in Neuroscience, May 2026. URL: https://doi.org/10.3389/fnins.2026.1808921, doi:10.3389/fnins.2026.1808921. This article has 1 citations and is from a peer-reviewed journal.
(chofflet2025alphaneurexinsinhealth pages 1-2): Nicolas Chofflet, Manni Wang, Mathilde Chofflet, and Hideto Takahashi. Alpha-neurexins in health and disease. Frontiers in Molecular Neuroscience, Nov 2025. URL: https://doi.org/10.3389/fnmol.2025.1716782, doi:10.3389/fnmol.2025.1716782. This article has 4 citations.
(chofflet2025alphaneurexinsinhealth pages 6-7): Nicolas Chofflet, Manni Wang, Mathilde Chofflet, and Hideto Takahashi. Alpha-neurexins in health and disease. Frontiers in Molecular Neuroscience, Nov 2025. URL: https://doi.org/10.3389/fnmol.2025.1716782, doi:10.3389/fnmol.2025.1716782. This article has 4 citations.
(cuttler2021emergingevidenceimplicating pages 3-3): Katelyn Cuttler, Maryam Hassan, Jonathan Carr, Ruben Cloete, and Soraya Bardien. Emerging evidence implicating a role for neurexins in neurodegenerative and neuropsychiatric disorders. Open Biology, Oct 2021. URL: https://doi.org/10.1098/rsob.210091, doi:10.1098/rsob.210091. This article has 68 citations and is from a peer-reviewed journal.
(khoja2023advancesinneurexin pages 4-5): Sheraz Khoja, Mulatwa T. Haile, and Lulu Y. Chen. Advances in neurexin studies and the emerging role of neurexin-2 in autism spectrum disorder. Frontiers in Molecular Neuroscience, Feb 2023. URL: https://doi.org/10.3389/fnmol.2023.1125087, doi:10.3389/fnmol.2023.1125087. This article has 38 citations.
(liu2026rolesofnrxn1 pages 3-4): Jia-Xiang Liu, Yanxuan Zhang, Ruijia Jin, Yuxin Zhu, and Jian-Ru Chen. Roles of nrxn1 in neuropsychiatric disorders: from genetic lesion to molecular mechanism. Frontiers in Neuroscience, May 2026. URL: https://doi.org/10.3389/fnins.2026.1808921, doi:10.3389/fnins.2026.1808921. This article has 1 citations and is from a peer-reviewed journal.
(chofflet2025alphaneurexinsinhealth pages 3-4): Nicolas Chofflet, Manni Wang, Mathilde Chofflet, and Hideto Takahashi. Alpha-neurexins in health and disease. Frontiers in Molecular Neuroscience, Nov 2025. URL: https://doi.org/10.3389/fnmol.2025.1716782, doi:10.3389/fnmol.2025.1716782. This article has 4 citations.
(chofflet2024structuralandfunctional pages 9-10): Nicolas Chofflet, Yusuke Naito, Anthony John Pastore, Nirmala Padmanabhan, Phuong Trang Nguyen, Christian Poitras, Benjamin Feller, Nayoung Yi, Jeremie Van Prooijen, Husam Khaled, Benoit Coulombe, Steven J. Clapcote, Steve Bourgault, Tabrez J. Siddiqui, Gabby Rudenko, and Hideto Takahashi. Structural and functional characterization of the igsf21-neurexin2α complex and its related signaling pathways in the regulation of inhibitory synapse organization. Frontiers in Molecular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fnmol.2024.1371145, doi:10.3389/fnmol.2024.1371145. This article has 9 citations.
(chofflet2024structuralandfunctional pages 7-9): Nicolas Chofflet, Yusuke Naito, Anthony John Pastore, Nirmala Padmanabhan, Phuong Trang Nguyen, Christian Poitras, Benjamin Feller, Nayoung Yi, Jeremie Van Prooijen, Husam Khaled, Benoit Coulombe, Steven J. Clapcote, Steve Bourgault, Tabrez J. Siddiqui, Gabby Rudenko, and Hideto Takahashi. Structural and functional characterization of the igsf21-neurexin2α complex and its related signaling pathways in the regulation of inhibitory synapse organization. Frontiers in Molecular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fnmol.2024.1371145, doi:10.3389/fnmol.2024.1371145. This article has 9 citations.
(chofflet2024structuralandfunctional pages 6-7): Nicolas Chofflet, Yusuke Naito, Anthony John Pastore, Nirmala Padmanabhan, Phuong Trang Nguyen, Christian Poitras, Benjamin Feller, Nayoung Yi, Jeremie Van Prooijen, Husam Khaled, Benoit Coulombe, Steven J. Clapcote, Steve Bourgault, Tabrez J. Siddiqui, Gabby Rudenko, and Hideto Takahashi. Structural and functional characterization of the igsf21-neurexin2α complex and its related signaling pathways in the regulation of inhibitory synapse organization. Frontiers in Molecular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fnmol.2024.1371145, doi:10.3389/fnmol.2024.1371145. This article has 9 citations.
(boxer2022neurexinsandtheir pages 9-10): Emma E. Boxer and Jason Aoto. Neurexins and their ligands at inhibitory synapses. Frontiers in Synaptic Neuroscience, Dec 2022. URL: https://doi.org/10.3389/fnsyn.2022.1087238, doi:10.3389/fnsyn.2022.1087238. This article has 40 citations.
(boxer2022neurexinsandtheir pages 8-9): Emma E. Boxer and Jason Aoto. Neurexins and their ligands at inhibitory synapses. Frontiers in Synaptic Neuroscience, Dec 2022. URL: https://doi.org/10.3389/fnsyn.2022.1087238, doi:10.3389/fnsyn.2022.1087238. This article has 40 citations.
(khoja2023advancesinneurexin pages 5-6): Sheraz Khoja, Mulatwa T. Haile, and Lulu Y. Chen. Advances in neurexin studies and the emerging role of neurexin-2 in autism spectrum disorder. Frontiers in Molecular Neuroscience, Feb 2023. URL: https://doi.org/10.3389/fnmol.2023.1125087, doi:10.3389/fnmol.2023.1125087. This article has 38 citations.
(juanes2026neurexin3βis pages 18-21): Rita Cervera Juanes, Clara Lowe, Kip Zimmerman, Frances Miller, Dongqin Zhu, Aidan McGrath-Conwell, Colin McArdle, Steve Gonzales, Rupak Khadka, Kimberly Raab-Graham, Betsy Ferguson, and Kathleen Grant. Neurexin 3β is downregulated in the prefrontal cortex following chronic ethanol use. Unknown journal, Aug 2026. URL: https://doi.org/10.21203/rs.3.rs-10283161/v1, doi:10.21203/rs.3.rs-10283161/v1.
(tromp2021neurexinsinautism pages 5-6): Alisha Tromp, Bryan Mowry, and Jean Giacomotto. Neurexins in autism and schizophrenia—a review of patient mutations, mouse models and potential future directions. Molecular Psychiatry, 26:747-760, Nov 2021. URL: https://doi.org/10.1038/s41380-020-00944-8, doi:10.1038/s41380-020-00944-8. This article has 132 citations and is from a highest quality peer-reviewed journal.
(chofflet2025alphaneurexinsinhealth pages 5-6): Nicolas Chofflet, Manni Wang, Mathilde Chofflet, and Hideto Takahashi. Alpha-neurexins in health and disease. Frontiers in Molecular Neuroscience, Nov 2025. URL: https://doi.org/10.3389/fnmol.2025.1716782, doi:10.3389/fnmol.2025.1716782. This article has 4 citations.
(gomez2021neurexinsmolecularcodes pages 10-12): Andrea M. Gomez, Lisa Traunmüller, and Peter Scheiffele. Neurexins: molecular codes for shaping neuronal synapses. Nature Reviews Neuroscience, 22:137-151, Jan 2021. URL: https://doi.org/10.1038/s41583-020-00415-7, doi:10.1038/s41583-020-00415-7. This article has 276 citations and is from a highest quality peer-reviewed journal.
(chofflet2025alphaneurexinsinhealth pages 11-12): Nicolas Chofflet, Manni Wang, Mathilde Chofflet, and Hideto Takahashi. Alpha-neurexins in health and disease. Frontiers in Molecular Neuroscience, Nov 2025. URL: https://doi.org/10.3389/fnmol.2025.1716782, doi:10.3389/fnmol.2025.1716782. This article has 4 citations.
(tromp2021neurexinsinautism pages 11-11): Alisha Tromp, Bryan Mowry, and Jean Giacomotto. Neurexins in autism and schizophrenia—a review of patient mutations, mouse models and potential future directions. Molecular Psychiatry, 26:747-760, Nov 2021. URL: https://doi.org/10.1038/s41380-020-00944-8, doi:10.1038/s41380-020-00944-8. This article has 132 citations and is from a highest quality peer-reviewed journal.
(khoja2023advancesinneurexin pages 10-10): Sheraz Khoja, Mulatwa T. Haile, and Lulu Y. Chen. Advances in neurexin studies and the emerging role of neurexin-2 in autism spectrum disorder. Frontiers in Molecular Neuroscience, Feb 2023. URL: https://doi.org/10.3389/fnmol.2023.1125087, doi:10.3389/fnmol.2023.1125087. This article has 38 citations.